ARK Genomic Revolution ETF (ARKG)
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable
ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?
The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.
Best ETF Areas of June
Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simultaneously engaging with potential acquirers.
COVID, Ukraine, ChatGPT Expose Thematic Fund Gaps
FactSet analysis shows thematic funds respond differently to market shocks, with some genomic ETFs rising after COVID while others lagged.
ARKG: Cathie Wood's Biotech Product Is In Rally Mode
ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% since July and beating the S&P 500 by 12 percentage points. The ETF's concentrated, small-cap, high-risk portfolio is supported by rising AUM, robust liquidity, and a bullish technical breakout.
ARKG: I'm Holding Off Buying For These 3 Reasons
I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lack of dividend yield make it less attractive compared to peer genomic ETFs with better performance and lower fees. Top holdings like Tempus AI, CRISPR Therapeutics, and Twist Bioscience are either overvalued or struggle with profitability, limiting ARKG's upside.
ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft
I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward profile, and focus on the genomics revolution, though it lacks a dividend yield. The ETF has rebounded 42% off April lows, outperforming the S&P 500, but faces seasonal headwinds and resistance near $28-$31.
Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again
It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Cathie Wood's Top Biotech Plays for February
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
Under-the-Radar Opportunities in ETFs
Over recent years, investors have sought safety within mega-cap tech stocks while searching for alpha within disruptive technology trends like artificial intelligence. Most investors can agree the AI theme has long-term growth potential, and the current market sell-off is a short-term hiccup.
ETF Prime: Islam Shares 2025's Top Trends and ETFs
On this week's episode of ETF Prime, Roxanna Islam, CFA, CAIA, head of sector & industry research at VettaFi, joined host Nate Geraci. The two discussed top ETF performers and trends this year as well as long-established asset managers finally joining the ETF industry.
ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends
I maintain a buy rating on ARK Genomic Revolution ETF (ARKG) due to improving momentum, potential lower interest rates, and a favorable M&A environment in 2025. Despite a 20% decline in 2024, ARKG's technical chart shows bullish potential with key support at $21-$22 and resistance at $28. ARKG is a small, actively managed ETF focused on genomics, with high exposure to small-cap stocks and a diversified mix of value, blend, and growth.
Best-Performing ETF Areas of Last Week
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
Interest Rate Regimes And ARKG: Underperformance Explained
ARKG's top holdings were replaced due to poor performance, highlighting the fund's vulnerability to interest rate changes and high concentration in cash-burning companies. ARKG underperformed significantly compared to peers and the Nasdaq, especially during tighter monetary conditions, due to its concentrated portfolio and high valuation multiples. Virtus, with a more diversified and less concentrated portfolio, outperformed ARKG, suggesting that ARKG needs restructuring to better handle interest rate changes.
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
Ark Funds pull exclusively from different slivers of the technology sector that also tend to be the most volatile. Economic conditions can make a bigger performance difference over the long term than most investors might expect.